Virios Therapeutics shares are trading higher after the company announced the Bateman Horne Center completed enrollment in its investigator-initiated, proof of concept LC study.
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics shares are trading higher after the company announced the Bateman Horne Center completed enrollment in its investigator-initiated, proof of concept LC study.
July 23, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virios Therapeutics shares are trading higher following the completion of enrollment in a proof of concept LC study by the Bateman Horne Center.
The completion of enrollment in a proof of concept study is a significant milestone for Virios Therapeutics, indicating progress in their clinical trials. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100